Amarin Corporation plc (AMRN)
| Market Cap | 247.61M -24.2% |
| Revenue (ttm) | 176.11M -22.3% |
| Net Income | -19.14M |
| EPS | -0.91 |
| Shares Out | 21.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81,223 |
| Open | 11.46 |
| Previous Close | 11.74 |
| Day's Range | 11.46 - 11.75 |
| 52-Week Range | 11.25 - 17.31 |
| Beta | 0.79 |
| Analysts | Strong Sell |
| Price Target | 12.50 (+6.38%) |
| Earnings Date | Oct 28, 2026 |
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaborat... [Read more]
Financial Performance
In 2025, Amarin Corporation's revenue was $213.65 million, a decrease of -6.55% compared to the previous year's $228.61 million. Losses were -$38.80 million, -52.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AMRN stock is "Strong Sell." The 12-month stock price target is $12.5, which is an increase of 6.38% from the latest price.
News
Amarin presents REDUCE-IT data on lipoprotein link to cardiovascular risk
Amarin (AMRN) announced new clinical data evaluating lipoprotein a and other apolipoprotein B containing lipoproteins as predictors of major adverse cardiovascular events, presented at the American He...
Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlight...
Amarin Corporation Earnings Call Transcript: Q3 2026
Q3 delivered the first profit in two years, with $9M operating cash flow and $324M cash and investments, while revenue fell on U.S. pricing pressure. International demand grew strongly, and EMT2 showed an overall-survival benefit despite missing its primary endpoint.
Amarin Corporation Earnings release: Q3 2026
Amarin Corporation released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Amarin Corporation Quarterly report: Q3 2026
Amarin Corporation has published its Q3 2026 quarterly earnings report on October 28, 2026.
Amarin Corporation Slides: Q3 2026
Amarin Corporation has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
Amarin Corporation Slides
Amarin Corporation has posted slides in relation to its latest quarterly earnings report, which was published on October 28, 2026.
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced...
Amarin announces EPA for Metastasis Trial 2 did not meet primary endpoint
Amarin (AMRN) highlighted findings from the EPA for Metastasis Trial 2, EMT2, a randomized, double-blind, placebo-controlled, multi-center, Phase 3 investigator-initiated trial sponsored by the Univer...
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of ...
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it...
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighte...
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced ...
Amarin reinstated with an Underweight at JPMorgan
JPMorgan analyst Jessica Fye reinstated coverage of Amarin (AMRN) with an Underweight rating and $13 price target The firm does not see significant downside from current levels, but believes Amarin’s…
Amarin Corporation Transcript: Transcript
Q2 2026 saw strong international growth for VASCEPA, especially in Europe via the Recordati partnership, and stable U.S. performance despite pricing pressure. Operating loss narrowed, cash flow remained positive, and restructuring drove significant cost savings.
Amarin Corporation Slides
Amarin Corporation has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Amarin Corporation Quarterly report
Amarin Corporation has published a quarterly earnings report on July 29, 2026.
Amarin Corporation Earnings release
Amarin Corporation released its earnings on July 29, 2026, summarizing the period's financial results.
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's ...
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announce...
Amarin Corporation Transcript: Transcript
Q2 2024 revenue declined year-over-year due to U.S. generic competition, but international growth, especially in Europe and China, offset some pressure. Cost-saving initiatives improved profitability, and the company remains focused on global expansion and maintaining U.S. market leadership.
Amarin Corporation Transcript: Transcript
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides Clinically Valid...
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, t...